1. Home
  2. HRMY vs OII Comparison

HRMY vs OII Comparison

Compare HRMY & OII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • OII
  • Stock Information
  • Founded
  • HRMY 2017
  • OII 1964
  • Country
  • HRMY United States
  • OII United States
  • Employees
  • HRMY N/A
  • OII N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • OII Oilfield Services/Equipment
  • Sector
  • HRMY Health Care
  • OII Energy
  • Exchange
  • HRMY Nasdaq
  • OII Nasdaq
  • Market Cap
  • HRMY 2.0B
  • OII 1.9B
  • IPO Year
  • HRMY 2020
  • OII N/A
  • Fundamental
  • Price
  • HRMY $31.89
  • OII $21.33
  • Analyst Decision
  • HRMY Strong Buy
  • OII Hold
  • Analyst Count
  • HRMY 9
  • OII 5
  • Target Price
  • HRMY $54.22
  • OII $28.00
  • AVG Volume (30 Days)
  • HRMY 611.9K
  • OII 662.0K
  • Earning Date
  • HRMY 08-05-2025
  • OII 07-23-2025
  • Dividend Yield
  • HRMY N/A
  • OII N/A
  • EPS Growth
  • HRMY 13.13
  • OII 67.93
  • EPS
  • HRMY 2.62
  • OII 1.78
  • Revenue
  • HRMY $744,852,000.00
  • OII $2,736,592,000.00
  • Revenue This Year
  • HRMY $20.10
  • OII $4.92
  • Revenue Next Year
  • HRMY $18.01
  • OII $3.22
  • P/E Ratio
  • HRMY $12.17
  • OII $12.04
  • Revenue Growth
  • HRMY 20.62
  • OII 10.04
  • 52 Week Low
  • HRMY $26.47
  • OII $15.46
  • 52 Week High
  • HRMY $41.61
  • OII $30.98
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 36.85
  • OII 62.79
  • Support Level
  • HRMY $32.39
  • OII $20.57
  • Resistance Level
  • HRMY $33.42
  • OII $22.09
  • Average True Range (ATR)
  • HRMY 1.06
  • OII 0.72
  • MACD
  • HRMY -0.47
  • OII 0.12
  • Stochastic Oscillator
  • HRMY 6.91
  • OII 75.16

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About OII Oceaneering International Inc.

Oceaneering International Inc is a provider of engineered services and products and robotic solutions to the offshore energy, defense, aerospace, manufacturing, and entertainment industries. A majority of its products are produced for the offshore oil and gas market. The company's business segments are Integrity Management and Digital Solutions, Subsea Robotics, Manufactured Products, Offshore Projects Group, and Aerospace and Defense Technologies. Maximum revenue is generated from its Subsea Robotics segment, which provides remotely operated vehicles (ROVs) for drill support and vessel-based services, underwater surveys, tooling, and other activities. Geographically, the company derives its key revenue from the United States, followed by Africa, Norway, Brazil, and other regions.

Share on Social Networks: